Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells.

Although we observed some expansion in the number of activated T cells (GrzB+CD8+ T cells) and tumor antigen-specific T cells (AH1+CD8+ T cells), the difference did not reach statistical significance.

also in 111,027 other papers